|
| 产品描述 |
| LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein. LY900009 inhibited plasma levels of amyloid-β peptide in a dose-dependent manner with 80-90% inhibition observed in the 30- to 60-mg cohorts. LY900009 is an orally available GSI (Aβ: IC50= 10.9−12.1 nM; Notch: IC50 = 14.1 nM) that was developed as a candidate therapeutic drug against AD (IDENTITY trial), which failed in phase III trials. |
| 化学结构 |
 |
| 化学名称 |
| (S)-2-hydroxy-3-methyl-N-((S)-1-(((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide |
| SMILES Code |
| CN1C([C@@H](NC([C@H](C)NC([C@@H](O)C(C)C)=O)=O)C2=C(C=CC=C2)C3=C1C=CC=C3)=O |
| 基本信息 |
产品编号:XM474
产品名称:LY900009
别名:LY900009; LY-900009; LY 900009.
CAS#:209984-68-9
分子式:C23H27N3O4
精确分子量:409.2002
分子量:409.486
|
| 物化性质 |
外观: 白色或类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
